Roquefort Therapeutics (LON:ROQ) Trading Up 4.3% – Here’s What Happened

Roquefort Therapeutics plc (LON:ROQ)’s stock price rose 4.3% during trading on Thursday . The company traded as high as GBX 2.40 ($0.03) and last traded at GBX 2.40 ($0.03). Approximately 1,310,260 shares changed hands during trading, a decline of 28% from the average daily volume of 1,827,140 shares. The stock had previously closed at GBX 2.30 ($0.03).

Roquefort Therapeutics Stock Up 6.0 %

The company has a quick ratio of 3.07, a current ratio of 0.79 and a debt-to-equity ratio of 12.37. The stock has a market cap of £3.22 million, a P/E ratio of -249.00 and a beta of 0.05. The company’s 50 day moving average price is GBX 3.92 and its two-hundred day moving average price is GBX 3.97.

Insider Buying and Selling at Roquefort Therapeutics

In other Roquefort Therapeutics news, insider Stephen Paul West bought 400,000 shares of the business’s stock in a transaction on Tuesday, February 4th. The shares were acquired at an average price of GBX 3 ($0.04) per share, with a total value of £12,000 ($14,886.49). 60.40% of the stock is currently owned by corporate insiders.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.